company background image
EAST

EastWest Bioscience TSXV:EAST Stock Report

Last Price

CA$0.025

Market Cap

CA$2.5m

7D

25.0%

1Y

25.0%

Updated

09 Aug, 2022

Data

Company Financials
EAST fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health0/6
Dividends0/6

EAST Stock Overview

EastWest Bioscience Inc., a vertically-integrated wellness company, manufactures and sells hemp nutritional products in Canada and the United States.

EastWest Bioscience Competitors

Price History & Performance

Summary of all time highs, changes and price drops for EastWest Bioscience
Historical stock prices
Current Share PriceCA$0.025
52 Week HighCA$0.045
52 Week LowCA$0.015
Beta0.80
1 Month Change25.00%
3 Month Change25.00%
1 Year Change25.00%
3 Year Change-54.55%
5 Year Changen/a
Change since IPO-85.71%

Recent News & Updates

Shareholder Returns

EASTCA PharmaceuticalsCA Market
7D25.0%0.04%0.3%
1Y25.0%-66.8%-2.0%

Return vs Industry: EAST exceeded the Canadian Pharmaceuticals industry which returned -66.3% over the past year.

Return vs Market: EAST exceeded the Canadian Market which returned -1.2% over the past year.

Price Volatility

Is EAST's price volatile compared to industry and market?
EAST volatility
EAST Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement13.4%
Market Average Movement10.8%
10% most volatile stocks in CA Market19.4%
10% least volatile stocks in CA Market4.3%

Stable Share Price: Insufficient data to determine EAST's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine EAST's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aRodney Gelineauhttps://www.eastwestbioscience.com

EastWest Bioscience Inc., a vertically-integrated wellness company, manufactures and sells hemp nutritional products in Canada and the United States. The company also operates Sangster’s Health Center stores that sells supplements and wellness products through its franchise locations and online ecommerce platform. In addition, it is involved in the property management business.

EastWest Bioscience Fundamentals Summary

How do EastWest Bioscience's earnings and revenue compare to its market cap?
EAST fundamental statistics
Market CapCA$2.52m
Earnings (TTM)CA$108.55k
Revenue (TTM)CA$703.10k

23.4x

P/E Ratio

3.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EAST income statement (TTM)
RevenueCA$703.10k
Cost of RevenueCA$293.78k
Gross ProfitCA$409.33k
Other ExpensesCA$300.78k
EarningsCA$108.55k

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.0011
Gross Margin58.22%
Net Profit Margin15.44%
Debt/Equity Ratio71.7%

How did EAST perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is EAST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EAST?

Other financial metrics that can be useful for relative valuation.

EAST key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7x
Enterprise Value/EBITDA-2.2x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does EAST's PE Ratio compare to its peers?

EAST PE Ratio vs Peers
The above table shows the PE ratio for EAST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average15.3x
CLAS Claritas Pharmaceuticals
0.4xn/aCA$944.7k
FUZN High Fusion
6.5xn/aCA$5.0m
J Lotus Ventures
32.5xn/aCA$5.8m
GRIN Grown Rogue International
21.7xn/aCA$15.4m
EAST EastWest Bioscience
23.4xn/aCA$2.5m

Price-To-Earnings vs Peers: EAST is expensive based on its Price-To-Earnings Ratio (23.4x) compared to the peer average (15.3x).


Price to Earnings Ratio vs Industry

How does EAST's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

Price-To-Earnings vs Industry: EAST is expensive based on its Price-To-Earnings Ratio (23.4x) compared to the Canadian Pharmaceuticals industry average (14.6x)


Price to Earnings Ratio vs Fair Ratio

What is EAST's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EAST PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio23.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate EAST's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of EAST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EAST's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EAST's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is EastWest Bioscience forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


75.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EastWest Bioscience has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of EAST’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • EastWest Bioscience competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has EastWest Bioscience performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


14.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: EAST has a large one-off gain of CA$3.5M impacting its April 30 2022 financial results.

Growing Profit Margin: EAST became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: EAST has become profitable over the past 5 years, growing earnings by 14.2% per year.

Accelerating Growth: EAST has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: EAST has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (72.5%).


Return on Equity

High ROE: EAST's Return on Equity (-0.02%) is considered low.


Discover strong past performing companies

Financial Health

How is EastWest Bioscience's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: EAST's short term assets (CA$321.6K) do not cover its short term liabilities (CA$3.8M).

Long Term Liabilities: EAST's short term assets (CA$321.6K) do not cover its long term liabilities (CA$422.3K).


Debt to Equity History and Analysis

Debt Level: EAST's net debt to equity ratio (71.1%) is considered high.

Reducing Debt: EAST's debt to equity ratio has increased from 60.9% to 71.7% over the past 5 years.

Debt Coverage: EAST's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if EAST's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies

Dividend

What is EastWest Bioscience current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate EAST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EAST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EAST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EAST's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as EAST has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average board tenure


CEO

Rodney Gelineau (52 yo)

no data

Tenure

CA$105,000

Compensation

Mr. Rodney Gelineau is Co-Founder, Chief Executive Officer, President and Director of EastWest Bioscience Inc. (Former Name: Harbour Star Capital Inc.). He served as the President and Chief Executive Offic...


CEO Compensation Analysis

Compensation vs Market: Rodney's total compensation ($USD81.50K) is below average for companies of similar size in the Canadian market ($USD186.89K).

Compensation vs Earnings: Rodney's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: EAST's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: EAST insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.2%.


Top Shareholders

Company Information

EastWest Bioscience Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: EastWest Bioscience Inc.
  • Ticker: EAST
  • Exchange: TSXV
  • Founded: 2016
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$2.517m
  • Shares outstanding: 100.66m
  • Website: https://www.eastwestbioscience.com

Location

  • EastWest Bioscience Inc.
  • 260 Okanagan Avenue East
  • Vancouver
  • British Columbia
  • V2A 3J8
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/09 00:00
Earnings2022/04/30
Annual Earnings2021/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.